IceCure Medical's New $4 Million Offering Signals Growth for Cryoablation Technology IceCure Medical Ltd. announces a $4 million registered direct offering alongside a concurrent private placement, enhancing its cryoablation technology market.

IceCure Medical's New $4 Million Offering Signals Growth for Cryoablation Technology #Israel #Caesarea #IceCure_Medical #Cryoablation #Nasdaq_ICCM

Collapse of unified administration in the Mashriq created chaos in which bad actors thrived. The #GreatGermanPilgrimage to Jerusalem was attacked at #Caesarea by Bedouin bandits on #ThisDayInHistory in 1065. Survivors were rescued two days later by the #Fatimid governor of Ramla.

IceCure's Promising 5-Year Study Results for Kidney Cancer Cryoablation Show High Recurrence-Free Rates IceCure Medical has revealed impressive five-year results from its ICESECRET study, highlighting significant recurrence-free rates for kidney cancer treatment, promoting its minimally invasive ProSense® technology.

IceCure's Promising 5-Year Study Results for Kidney Cancer Cryoablation Show High Recurrence-Free Rates #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Medical Welcomes Meir Peleg as Chief Financial Officer to Drive Growth IceCure Medical has appointed Meir Peleg as its CFO, bringing years of financial expertise to aid in the company's strategic growth in cryoablation technology.

IceCure Medical Welcomes Meir Peleg as Chief Financial Officer to Drive Growth #Israel #Caesarea #IceCure_Medical #ProSense #Meir_Peleg

Max Stock Limited Addresses Erez Nahum's Resignation as Board Director Max Stock Limited has provided clarifications regarding Erez Nahum's resignation, revealing a dispute with the board and governance concerns.

Max Stock Limited Addresses Erez Nahum's Resignation as Board Director #Israel #Max_Stock #Caesarea #Corporate_Governance #Erez_Nahum

Max Stock Limited Declares Cash Dividend for Shareholders on April 15, 2026 Max Stock Limited has announced a cash dividend of ILS 0.5723422 per share, amounting to ILS 80 million, set to be paid to shareholders.

Max Stock Limited Declares Cash Dividend for Shareholders on April 15, 2026 #Israel #Shareholders #Max_Stock #Caesarea #Cash_Dividend

Max Stock Limited Announces Impressive Financial Results for Q4 and Fiscal Year 2025 Max Stock Limited showcases robust Q4 and fiscal year 2025 financial results, reflecting solid revenue growth and improved profitability. Discover the details!

Max Stock Limited Announces Impressive Financial Results for Q4 and Fiscal Year 2025 #Israel #Max_Stock #Caesarea #retail

Max Stock Limited Confirms Departure of Senior Officer Nahum Erez Amid Resignation Max Stock Limited announces the resignation of Nahum Erez, a senior officer, effective March 15, 2026, with no special circumstances involved.

Max Stock Limited Confirms Departure of Senior Officer Nahum Erez Amid Resignation #Israel #Caesarea #Max_Stock_Limited #Nahum_Erez

IceCure Medical's ProSense® Cryoablation Gains FDA Approval for Breast Cancer Study The FDA has approved IceCure Medical's ProSense® cryoablation system for a post-marketing study in low-risk breast cancer treatment, engaging major U.S. medical institutions.

IceCure Medical's ProSense® Cryoablation Gains FDA Approval for Breast Cancer Study #United_States #Caesarea #IceCure_Medical #Cryoablation #ProSense

Turpaz Industries Reports Record Financial Growth for 2025 with Stable Expansion Strategy Turpaz Industries Ltd. announces outstanding financial results for 2025, boasting significant revenue growth and strategic acquisitions, marking a pivotal year for the company.

Turpaz Industries Reports Record Financial Growth for 2025 with Stable Expansion Strategy #Israel #Caesarea #Fragrance #flavor #Turpaz_Industries

IceCure Medical's ProSense Cryoablation: A Game-Changer for Breast Fibroadenoma Treatment IceCure Medical's recent study reveals the effectiveness of ProSense® cryoablation for treating breast fibroadenomas, fostering potential shifts in clinical guidelines.

IceCure Medical's ProSense Cryoablation: A Game-Changer for Breast Fibroadenoma Treatment #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Medical Marks Milestone in Kidney Cancer Cryoablation Study with 5-Year Follow-Up Outcomes IceCure Medical has completed a significant 5-year follow-up in its ICESECRET kidney cancer cryoablation study. Final analysis is anticipated by Q2 2026.

IceCure Medical Marks Milestone in Kidney Cancer Cryoablation Study with 5-Year Follow-Up Outcomes #Israel #Caesarea #IceCure_Medical #ProSense #Kidney_Cancer

IceCure Medical Announces CFO Departure After Key Achievements in Nine Years IceCure Medical has announced the departure of CFO Ronen Tsimerman after nearly a decade, highlighting significant milestones achieved during his tenure.

IceCure Medical Announces CFO Departure After Key Achievements in Nine Years #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

Max Stock Limited Announces a Significant Stake Increase by New Investor for Growth Max Stock Limited has reported a new significant investment from Meitav Investment House, indicating a promising future for the company.

Max Stock Limited Announces a Significant Stake Increase by New Investor for Growth #Israel #Max_Stock #Caesarea #Meitav_Investment #Investment_House

IceCure Applauds ASBrS for Including Cryoablation in Breast Cancer Guidelines IceCure celebrates the American Society of Breast Surgeons' new guidelines, endorsing cryoablation for low-risk breast cancer patients. This marks a significant advancement in breast cancer treatment options.

IceCure Applauds ASBrS for Including Cryoablation in Breast Cancer Guidelines #Israel #Caesarea #Cryoablation #IceCure #ASBrS

IceCure Medical Reports Record Sales of ProSense® and Strengthens Market Position IceCure Medical reports record-breaking 2025 sales of ProSense®, following FDA approval for treating low-risk breast cancer, with strong market demand in the U.S.

IceCure Medical Reports Record Sales of ProSense® and Strengthens Market Position #Israel #Caesarea #IceCure_Medical #ProSense® #Eyal_Shamir

Max Stock Limited Announces Holdings of Interested Parties and Senior Officers Max Stock Limited discloses the holdings of its interested parties and senior officers as of December 31, 2025. Key stakeholders have been identified, emphasizing the company's growth and governance.

Max Stock Limited Announces Holdings of Interested Parties and Senior Officers #Securities #Israel #Caesarea #Holdings #Max_Stock_Limited

IceCure Medical Anticipates Record Sales in North America Following FDA Clearance of ProSense® Cryoablation System IceCure Medical is set to report record fourth quarter sales in North America, thanks to FDA's approval of the ProSense® system for low-risk breast cancer treatment.

IceCure Medical Anticipates Record Sales in North America Following FDA Clearance of ProSense® Cryoablation System #USA #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure's ProSense® Cryoablation Gains Traction at RSNA 2025 Annual Meeting with Promising New Studies IceCure Medical's ProSense® Cryoablation was showcased in four independent breast cancer studies at the RSNA 2025 Annual Meeting, emphasizing its effectiveness and growing acceptance in non-surgical treatments.

IceCure's ProSense® Cryoablation Gains Traction at RSNA 2025 Annual Meeting with Promising New Studies #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

IceCure Medical Advances Cryoablation Technology with New Patent in China for Improved Patient Outcomes IceCure Medical has received a Notice of Patent Allowance in China, enhancing their cryoablation systems. This advances patient care significantly.

IceCure Medical Advances Cryoablation Technology with New Patent in China for Improved Patient Outcomes #Israel #Caesarea #IceCure_Medical #Cryoablation #ProSense

#quotes #books #booksky #excerpts #citations #constantiusII #crawford #constantius #rome #roman #christianity #earlychristianity #4thCentury #antioch #syria #athanasius #council #bishop #embezzlement #summons #capadocia #turkey #caesarea #emperor

Max Stock Limited Notifies Major Share Transfer by Controlling Shareholder Max Stock Limited has reported a significant sale of shares by Moose Holdco, altering the controlling shareholder dynamics and impacting the company's market position.

Max Stock Limited Notifies Major Share Transfer by Controlling Shareholder #Israel #Max_Stock #Caesarea #Moose_Holdco #AMI_Foundation

Max Stock Limited Announces Solid Financial Results for Q3 2025 with Leadership Changes Max Stock Limited reveals impressive third quarter 2025 financial results, including increased revenue and a new CFO appointment, indicating promising growth.

Max Stock Limited Announces Solid Financial Results for Q3 2025 with Leadership Changes #Israel #Max_Stock #Caesarea #financial_results #Paz_Oz

IceCure Medical Faces Nasdaq Minimum Bid Price Notification: Next Steps outlined IceCure Medical Ltd. has announced that it has received a Nasdaq notification regarding minimum bid price non-compliance, sparking a 180-day compliance period.

IceCure Medical Faces Nasdaq Minimum Bid Price Notification: Next Steps outlined #Israel #Caesarea #IceCure_Medical #Nasdaq_Listing #ICCM

Turpaz Industries Achieves Remarkable Growth and Expansion Through Strategic Acquisitions Turpaz Industries showcases impressive sales growth of 57.4% in Q3 2025. The company continues expanding globally with ongoing acquisitions.

Turpaz Industries Achieves Remarkable Growth and Expansion Through Strategic Acquisitions #Israel #Caesarea #Turpaz_Industries #fragrances #Flavors

IceCure Medical Elevates Shay Levav to COO to Enhance Commercial Expansion IceCure Medical has named Shay Levav as Chief Operating Officer, boosting its leadership team as the company expands following FDA clearance for ProSense®.

IceCure Medical Elevates Shay Levav to COO to Enhance Commercial Expansion #Israel #Caesarea #IceCure_Medical #ProSense #Shay_Levav

Nitinotes Achieves CE Mark Approval for Revolutionary EndoZip Suturing System in Obesity Treatment Nitinotes Ltd. has secured CE Mark approval for the EndoZip™ System, transforming endoscopic sleeve gastroplasty procedures in Europe.

Nitinotes Achieves CE Mark Approval for Revolutionary EndoZip Suturing System in Obesity Treatment #Israel #Caesarea #Obesity_Treatment #EndoZip #Nitinotes

Nitinotes' EndoZip™ Receives CE Mark, Revolutionizing Obesity Treatment with Automated Suturing System Nitinotes Ltd. is set to transform obesity treatment with its newly CE Mark approved EndoZip™ system, enabling efficient outpatient endoscopic procedures.

Nitinotes' EndoZip™ Receives CE Mark, Revolutionizing Obesity Treatment with Automated Suturing System #Israel #Caesarea #ESG #EndoZip #Nitinotes

IceCure's Innovative Cryoablation System Enhances Lung Cancer Survival Rates Significantly IceCure's Cryoablation System, in combination with SBRT, leads to a remarkable 92% disease-specific survival rate for lung cancer patients, significantly improving outcomes.

IceCure's Innovative Cryoablation System Enhances Lung Cancer Survival Rates Significantly #Israel #Caesarea #IceCure_Medical #Cryoablation #SBRT

Max Stock Limited Reports Updated Holdings of Directors and Interested Parties as of September 30, 2025 Max Stock Limited has published an immediate report detailing the holdings of its interested parties and senior officers as of September 30, 2025. This report highlights significant stakeholders and their respective shares.

Max Stock Limited Reports Updated Holdings of Directors and Interested Parties as of September 30, 2025 #Israel #Max_Stock #Caesarea #Stock_Holdings